Alembic Pharmaceuticals receives USFDA approval for Darolutamide Tablets, 300 mg
Mumbai, May 14 -- Alembic Pharmaceuticals (Alembic) today announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Darolutamide Tablets, 300 mg.
Published by HT Digital Content Services with permission from Capital Market....
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.